V Square Quantitative Management LLC Sells 3,466 Shares of Illumina, Inc. (NASDAQ:ILMN)

V Square Quantitative Management LLC trimmed its stake in Illumina, Inc. (NASDAQ:ILMN) by 85.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 582 shares of the life sciences company’s stock after selling 3,466 shares during the period. V Square Quantitative Management LLC’s holdings in Illumina were worth $61,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Trivant Custom Portfolio Group LLC grew its holdings in shares of Illumina by 166.7% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock valued at $27,000 after purchasing an additional 125 shares during the last quarter. Versant Capital Management Inc lifted its stake in shares of Illumina by 292.9% in the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after acquiring an additional 246 shares during the last quarter. Wetzel Investment Advisors Inc. purchased a new stake in Illumina during the 4th quarter valued at about $37,000. Massmutual Trust Co. FSB ADV grew its position in Illumina by 86.8% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock worth $39,000 after acquiring an additional 132 shares during the last quarter. Finally, MeadowBrook Investment Advisors LLC purchased a new position in Illumina in the 4th quarter worth approximately $42,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Stock Up 3.5 %

Shares of NASDAQ:ILMN traded up $4.31 during trading hours on Thursday, hitting $126.59. The company’s stock had a trading volume of 140,598 shares, compared to its average volume of 2,115,427. The firm’s fifty day moving average price is $114.07 and its 200 day moving average price is $122.62. Illumina, Inc. has a 52 week low of $89.00 and a 52 week high of $174.52. The company has a market capitalization of $20.17 billion, a price-to-earnings ratio of -15.00 and a beta of 1.15. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.75 and a quick ratio of 1.36.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.24. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same quarter in the previous year, the firm earned $0.32 earnings per share. The firm’s quarterly revenue was down 5.4% compared to the same quarter last year. As a group, research analysts expect that Illumina, Inc. will post 1.5 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Royal Bank of Canada restated an “outperform” rating and set a $242.00 price target on shares of Illumina in a report on Wednesday. JPMorgan Chase & Co. reduced their target price on Illumina from $130.00 to $125.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Barclays upgraded Illumina from an “underweight” rating to an “equal weight” rating and set a $125.00 target price for the company in a research note on Wednesday. Piper Sandler decreased their price objective on Illumina from $200.00 to $195.00 and set an “overweight” rating for the company in a report on Tuesday. Finally, TD Cowen raised Illumina from a “hold” rating to a “buy” rating and raised their price objective for the company from $126.00 to $144.00 in a research report on Wednesday. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, Illumina currently has an average rating of “Hold” and a consensus price target of $151.55.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.